No Specific Guidance Available for Leflunomide Perioperative Management in CABG
The available evidence does not provide specific recommendations for holding leflunomide before or after CABG surgery. Based on general perioperative principles for DMARDs and the drug's pharmacology, leflunomide can be continued perioperatively without interruption.
Rationale for Continuation
Evidence from Perioperative DMARD Management
Conventional DMARDs, including leflunomide, can be continued through the perioperative period 1. This guidance applies to elective surgery in patients with inflammatory rheumatic diseases. The evidence suggests that continuing these medications does not significantly increase surgical complications while preventing disease flares.
Leflunomide-Specific Considerations
The FDA labeling for leflunomide does not address perioperative management or surgical timing 2. Key pharmacologic features relevant to surgical planning include:
- Long half-life: The active metabolite (M1) has an extended elimination period
- Immunosuppressive effects: Potential for increased infection risk, though this is primarily a concern with severe immunodeficiency 2
- Hepatotoxicity monitoring: Requires baseline and regular ALT monitoring, but no specific surgical contraindications 2
Contrast with Antiplatelet Agents
The extensive CABG guidelines focus on antiplatelet therapy management but make no mention of DMARDs like leflunomide 3, 4, 3. For context:
- Aspirin: Continue perioperatively 5, 6
- Clopidogrel/ticagrelor: Hold 5 days before elective CABG 3, 5, 7
- Prasugrel: Hold 7 days before elective CABG 3, 5, 7
Practical Management Algorithm
Before CABG
- Continue leflunomide at the current dose through surgery
- Ensure recent ALT monitoring is documented (within past month)
- Verify no active severe infection
After CABG
- Resume leflunomide immediately postoperatively once oral intake is tolerated
- No washout period required
- Monitor for wound healing and infection as standard post-CABG care
Important Caveats
When to Consider Holding
If the patient has:
- Active severe infection: May require drug elimination procedure with cholestyramine 2
- Significant hepatotoxicity: ALT >3× ULN requires discontinuation and cholestyramine washout 2
- Severe immunodeficiency or bone marrow suppression: Leflunomide is not recommended 2
Monitoring Requirements
Maintain standard leflunomide monitoring perioperatively:
- Complete blood count (baseline and monthly for 6 months, then every 6-8 weeks) 2
- Liver enzymes (monthly for 6 months, then every 6-8 weeks) 2
- Blood pressure monitoring 2
Drug Elimination Procedure (if needed)
If urgent discontinuation is required:
- Cholestyramine 8g three times daily for 11 days, OR
- Activated charcoal 50g four times daily for 11 days 2
This rapidly reduces M1 plasma concentrations but is rarely necessary for routine CABG surgery.